Trial · NCT07586826
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Platelet Response Rate at Week 12 | From randomization to Week 12 | Percentage of participants with platelet count \>50 x 10\^9/L in at least 2 of the last 3 scheduled platelet assessments up to Week 12. Platelet transfusion or other rescue/supportive treatment will not be counted as a platelet response. |
| Secondary | Sustained Platelet Response Rate During Weeks 13 to 24 | Weeks 13 through 24 | Percentage of participants with platelet count \>50 x 10\^9/L in at least 2 of the last 3 scheduled platelet assessments during Weeks 13 to 24 and without rescue therapy during this period. |
| Secondary | Complete Response Rate | Up to Week 24 | Percentage of participants with platelet count \>=100 x 10\^9/L and no bleeding for at least 2 consecutive weeks. |
| Secondary | Partial Response Rate | Up to Week 24 | Percentage of participants with platelet count \>=30 x 10\^9/L and at least 2 times the baseline platelet count, with no bleeding. |
| Secondary | Duration of Response | From first documented response to Week 24 | Among responders, time from first achievement of platelet response to platelet count \<30 x 10\^9/L or the end of study follow-up. |
| Secondary | Time to Response | From treatment start to Week 24 | Time from treatment start to the first platelet count \>=30 x 10\^9/L. |
| Secondary | Change in Platelet Count Over Time | Baseline; weekly during Weeks 1 to 12; every 2 weeks during Weeks 13 to 24 | Change in peripheral blood platelet count from baseline at scheduled study visits. |
| Secondary | Platelet Transfusion Requirement | From treatment start to Week 24 | Frequency and total amount of platelet transfusions during treatment and follow-up. |
| Secondary | Incidence of Bleeding Events | From treatment start to Week 24 | Percentage of participants with any bleeding event and severity of bleeding events recorded during the study. |
| Secondary | Incidence of Adverse Events and Serious Adverse Events | From first dose to Week 24 | Adverse events and serious adverse events will be recorded and graded according to CTCAE version 5.0 and summarized by treatment arm. |
| Secondary | Incidence of Thromboembolic Events | From first dose to Week 24 | Percentage of participants with confirmed thromboembolic events during treatment and follow-up. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07586826/registered